ERBB2 and breast cancer: Despite recent advances in diagnosis and treatment, patients with TNBC have been shown to have the highest rate of recurrence within the first five years after diagnosis compared with hormone receptor-positive (HR+) and HER-2/neu receptor-positive (HER2+) breast cancer patients [12].